Top

Published in:

01-06-2009 | Original Paper

Interstitial continuous infusion therapy in a malignant glioma model in rats

Authors: Yuichi Tange, Akihide Kondo, Merrill J. Egorin, Barbara Mania-Farnell, Georgy M. Daneriallis, Hiromichi Nakazaki, Simone T. Sredni, Veena Rajaram, Stewart Goldman, Marcelo B. Soares, Tadanori Tomita

Published in: Child's Nervous System | Issue 6/2009

Abstract

Purpose

Local direct delivery of chemotherapeutic agents for the treatment of brain tumors is an area of focus in the development of new therapeutic paradigms. These techniques need improvement, especially in terms of drug retention in brain tissue.

Materials and methods

In this study, we used a rat glioma model to examine carboplatin distribution, as measured by platinum penetration, after delivery via interstitial continuous (i.c.) infusion. We also examined rat survival times in response to carboplatin and oxaliplatin. I.C. infusion, a modified version of convection-enhanced delivery (CED) for local drug delivery, uses low volume (1 μl per hour) continuous infusion directly into the tumor.

Results

I.C. infusion produced a nearly 360-fold higher concentration of platinum in tumor tissue and significantly prolonged rodent survival time compared to intraperitoneal (i.p.) infusion.

Conclusions

We showed i.c. infusion allows for circumvention of the blood–brain barrier, focused drug distribution, and sustained drug delivery. This method could be a promising strategy for treating brain tumors.

Wolff JE, Trilling T, Mölenkamp G, Egeler RM, Jürgens H (1999) Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 125:481–486PubMedCrossRef

Chamberlain MC (2006) Treatment options for glioblastoma. Neurosurg Focus 20:E19PubMedCrossRef

Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Fiamengo SA, Neuwelt EA (1998) Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery 43:879–886PubMedCrossRef

Groothuis DR (2000) The blood–brain and blood–tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2:45–59PubMedCrossRef

Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104:29–45PubMedCrossRef

Brem H, Mahaley MS Jr, Vick NA, Black KL, Schold SC Jr, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW, Kenealy JN (1991) Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74:441–446PubMed

Tomita T (1991) Interstitial chemotherapy for brain tumors: review. J Neurooncol 10:57–74PubMedCrossRef

Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH (1995) Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82:1021–1029PubMed

Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH (1999) Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90:315–320PubMed

10.

Khan A, Jallo GI, Liu YJ, Carson BS Sr, Guarnieri M (2005) Infusion rates and drug distribution in brain tumor models in rats. J Neurosurg 102(Suppl.):53–58PubMed

11.

Degen JW, Walbridge S, Vortmeyer AO, Oldfield EH, Lonser RR (2003) Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg 99:893–898PubMedCrossRef

12.

Saito R, Bringas JR, Panner A, Tamas M, Pieper RO, Berger MS, Bankiewicz KS (2004) Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 64:6858–6862PubMedCrossRef

13.

Lévi F, Metzger G, Massari C, Milano G (2000) Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38:1–21PubMedCrossRef

14.

Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H (2004) Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res 21:891–894PubMedCrossRef

15.

Rochard E, Barthes D, Courtois P (1994) Stability and compatibility study of carboplatin with three portable infusion pump reservoirs. Int J Pharm 101:257–262CrossRef

16.

Kroin JS, Penn RD (1982) Intracerebral chemotherapy: chronic microinfusion of cisplatin. Neurosurgery 10:349–354PubMedCrossRef

17.

Chang MJ, Yu WD, Reyno LM, Modzelewski RA, Egorin MJ, Erkmen K, Vlock DR, Furmanski P, Johnson CS (1994) Potentiation by interleukin 1α of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model. Cancer Res 54:5380–5386PubMed

18.

Erkmen K, Egorin MJ, Reyno LM, Morgan R Jr, Doroshow JH (1995) Effects of storage on the binding of carboplatin to plasma. Cancer Chemother Pharmacol 35:254–256PubMedCrossRef

19.

Butowski NA, Sneed PK, Chang SM (2006) Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 24:1273–1280PubMedCrossRef

20.

Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, Berger MS, Chang S, Glioma Outcomes Investigators (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99:467–473PubMed

21.

Sugiyama S, Yamashita Y, Kikuchi T, Saito R, Kumabe T, Tominaga T (2007) Safety and efficacy of convection-enhanced delivery of ACNU, a hydrophilic nitrosourea, in intracranial brain tumor. J Neurooncol 82:41–47PubMedCrossRef

22.

Doz F, Berens ME, Dougherty DV, Rosenblum ML (1991) Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. J Neurooncol 11:27–35PubMedCrossRef

23.

Wang PP, Frazier J, Brem H (2002) Local drug delivery to the brain. Adv Drug Deliv Rev 54:987–1013PubMedCrossRef

24.

Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436PubMedCrossRef

25.

Chen W, Lu DR (1999) Carboplatin-loaded PLGA microspheres for intracerebral injection: formulation and characterization. J Microencapsul 16:551–563PubMedCrossRef

26.

Carson BS Sr, Wu Q, Tyler B, Sukav L, Raychaudhuri R, DiMeco F, Clatterbuck RE, Olivi A, Guarnieri M (2002) New approach to tumor therapy for inoperable areas of the brain: chronic intraparenchymal drug delivery. J Neurooncol 60:151–158PubMedCrossRef

27.

Friesen C, Herr I, Krammer PH, Debatin KM (1996) Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2:574–577PubMedCrossRef

28.

Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, Kupfer A (1995) Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med. 1:129–134PubMedCrossRef

Title: Interstitial continuous infusion therapy in a malignant glioma model in rats
Authors: Yuichi Tange
Akihide Kondo
Merrill J. Egorin
Barbara Mania-Farnell
Georgy M. Daneriallis
Hiromichi Nakazaki
Simone T. Sredni
Veena Rajaram
Stewart Goldman
Marcelo B. Soares
Tadanori Tomita
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Child's Nervous System / Issue 6/2009
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI: https://doi.org/10.1007/s00381-008-0805-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Interstitial continuous infusion therapy in a malignant glioma model in rats

Abstract

Purpose

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2009

Metachronous gliomas following cranial irradiation for mixed germ cell tumors

Pathophysiological mechanism of ipsilateral cerebral and brainstem hemiatrophy in basal ganglia germ cell tumors: case report

Do we really need class 1 evidence results to give adjuvant radiation therapy to childhood intracranial ependymomas?

Epilepsy surgery could be considered a line of defense against sudden unexpected death in epilepsy

Treatment factors associated with outcomes in children less than 3 years of age with CNS tumours

Atypical teratoid/rhabdoid tumor of the central nervous system: clinicopathologic and immunohistochemical features of four cases